Odunsi K, Qian F, Matsuzaki J, Mhawech-Fauceglia P, Andrews C, Hoffman EW, Pan L. Ritter G, Villella J, Thomas B, Rodabaugh K, Lele S, Shrikant P, Old LJ, Gnjatic S. (2007) Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci U S A, 104(31):12837-12842.
Matsuzaki J, Qian F, Luescher I, Lele S, Ritter G, Shrikant PA, Gnjatic S, Old LJ, Odunsi K. (2008) Recognition of naturally processed and ovarian cancer reactive CD8+ T cell epitopes within a promiscuous HLA class II T-helper region of NY-ESO-1. Cancer Immunol Immunother, 57(8):1189-1195.
Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, Beck A, Miller A, Tsuji T, Eppolito C, Qian F, Lele S, Shrikant P, Old LJ, Odunsi K. (2010) NY-ESO-1 specific tumor infiltrating CD8+ T cells in human ovarian cancer: negative regulation by LAG-3 and PD-1. Proc Natl Acad Sci U S A, 107(17):7875-7880.
Odunsi K, Matsuzaki J, Karbach J, Neumann A, Mhawech-Fauceglia P, Miller A, Beck A, Morrison CD, Ritter G, Godoy H, Lele S, Dupont N, Edwards R, Shrikant P, Old LJ, Gnjatic S, Jager E. (2012) Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proc Natl Acad Sci U S A, 109(15):5797-5802.
Tsuji T, Matsuzaki J, Caballero OL, Jungbluth AA, Ritter G, Odunsi K, Old LJ, Gnjatic S. (2012) Heat shock protein 90-mediated peptide-selective presentation of cytosolic tumor antigen for direct recognition of tumors by CD4+ T cells. J Immunol, 188(8):3851-3858.
Odunsi K, Matsuzaki J, James S, Mhawech-Fauceglia P, Tsuji T, Miller A, Zhang W, Akers S, Griffiths E, Miliotto A, Beck A, Batt C, Ritter G, Lele S, Gnjatic S, Karpf A. (2013) Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer. Cancer Immunol Res, 2(1):37-49.
Matsuzaki J, Tsuji T, Luescher I, Old L, Shrikant P, Gnjatic S, Odunsi K. (2014) Non-classical antigen processing pathways are required for MHC class II-restricted direct tumor recognition by NY-ESO-1-specific CD4+ T cells. Cancer Immunol Res, 2(4):341-350.